Many or several newly developed vaccines were used for the past two months that were approved by the US-FDA for emergency use ( EUA ) as preventive measures for protection against CoViD19.
And several peer-reviewed studies had shown that the new CoViD19 vaccines serve their purpose well enough but recently the effectiveness and efficacy of the vaccine were put to the test by the newly emerging variants of the SARS-CoV-2 virus.
Thanks to the genomic surveillance monitoring of several scientific groups that keeps an alert eye on the genetic variations of the novel virus as it continues to circulate and infects people around the globe. As it is now observed that the newly developed vaccines had little or probably will not work against the newly emerging strains or variants of the novel virus.
Since the start of the novel pandemic last December of 2019, people around the world desperately clamored and wanted a definite treatment for CoViD19, and health authorities of many wealthy nations in collaboration with big pharmaceutical industries recently develop novel treatment strategies against SARS-CoV-2 such as antivirals, immune modulators, monoclonal antibodies or mabs and especially the most awaited part which is the availability of the vaccines that can be used as more of a preventive approach. The new vaccines if given to the general population will result in the ultimate goal of ” herd immunity ” and that can protect us from the onslaught of the novel virus.
The general public is well aware of the fact that many repurposed drugs are used for the treatment of the novel disease and that the vaccines were made available to the population at lightning speed pace. Everybody relies too much on the availability and the effectiveness of the vaccines as a preventative approach in the mitigation of the viral spread. And as the newly developed vaccines were used and inoculated to the privileged recipients globally, multiple problems were encountered by health authorities in their respective locales.
Aside from the grim reality that many cannot avail of the vaccines may be due to the limited vaccine supply, its high price, hard-to-reach areas/locations, racial/ethnic disparities, non-availability of vaccine storage, or for any other reasons. But the big problem occurred from the serious adverse effect or event observed by some vaccinees post inoculation that was so serious enough that it kills the recipient/s although it was stated that the adverse event is very rare.
In anyways the vaccine strategy and protocol really does serve their purpose for many patients were saved from the disease and the benefits outweigh the risks. But as many had observed that the newly developed vaccines with regards to their effectiveness and efficacy wane over time as the new SARS-CoV-2 variants are emerging fast with a high transmission rate and causing more severe disease manifestation to the susceptible person. The big question now is how will the human race keep up with the emergence of a highly transmissible variant that causes increasing disease severity. Please keep reading as health experts and vaccine scientists devise a strategic plan to address such a problem.
Ingeniously, Innovatively Novel Vaccine Measure And Strategy Against Emerging SARS-CoV-2 Variants:
1.) Heterologous Prime Boosting.
Is an ingenious innovative strategy designed to increase the efficacy and effectiveness of the novel vaccines against the newly emerging SARS-CoV-2 variants that are now circulating and cause an increasing disease severity with a high person-to-person viral transmission rate.
Heterologous prime boosting is a countermeasure technique whereby using two alternating different CoViD19 vaccines. The patient or vaccinee will be given an initial CoViD19 vaccine to initially trigger or prime an immune response then after 4 to 12 weeks the vaccinee will receive another different type of vaccine as a second dose injection or as a booster injection to further mount a robust immune response. So the patient can receive an mRNA Astrazeneca vaccine as a first dose and then on the 4th to 12th week after the first vaccine injection the recipient will receive a Pfizer BioNTech or a Johnson & Johnson Janssen viral vector vaccine or a protein subunit vaccine in the form of Novavax injection considered as a second or booster dose vaccine injection. Heterologous Prime boosting or COM-COV 1 and 2 ( Comparing CoViD19 Vaccine Schedule Combinations ) Vaccine Trial 1 and 2 are currently being studied by the Oxford Vaccine Group in the United Kingdom. The Chief Investigator of the study is Associate Professor Matthew Snape and funded by the Vaccine Task Force and The National Institute for Health Research ( NIHR ).